# Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

> **NCT05450562** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 33 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **BIOLOGICAL:** SAR444200
- **BIOLOGICAL:** Atezolizumab

## Key facts

- **NCT ID:** NCT05450562
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-20
- **Primary completion:** 2025-12-22
- **Final completion:** 2025-12-22
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Early discontinuation based on strategic sponsor decision not driven by any safety concerns
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05450562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05450562, "Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05450562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*